What is Natco Pharma Ltd (NATCOPHARM) share price return in the past 10 years?

Natco Pharma Ltd share price has appreciated 3.1% annually (CAGR) over the past ten years.

What is the share price of Natco Pharma Ltd (NATCOPHARM)?

Company share prices are keep on changing according to the market conditions. The current trading price of Natco Pharma Ltd (NATCOPHARM) on 24-Sep-2026 16:59:59 at 16:59 is 841.85.

What is the P/E ratio of Natco Pharma?

The latest standalone P/E ratio of Natco Pharma as of 24-Sep-2026 is 16.90.

What is the P/B ratio of Natco Pharma Ltd (NATCOPHARM)?

The latest standalone P/B ratio of Natco Pharma Ltd (NATCOPHARM) as of 24-Sep-2026 is 1.75.

What is the 52-week high and low of Natco Pharma Ltd (NATCOPHARM)?

The 52-week high of Natco Pharma Ltd (NATCOPHARM) is Rs. 1226.10 and the 52-week low is Rs. 789.30.

Natco Pharma Ltd (NATCOPHARM)

Name: Natco Pharma Ltd (NATCOPHARM)
Brand: Natco Pharma

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524816 NSE: NATCOPHARM Pharmaceuticals & Drugs | Small Cap | Natco Pharma Share Price

₹841.85 4.00 (0.48%)

As on 24-Sep'26 16:59

Natco Pharma Ltd (NATCOPHARM)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524816 NSE: NATCOPHARM Pharmaceuticals & Drugs | Small Cap | Natco Pharma Share Price

₹841.85 4.00 (0.48%)

As on 24-Sep'26 16:59

Key Metrics

Valuation Multiples

Market Cap

₹15,078 Cr.

Current Price

₹841.9

52-Week Low / High

₹789 / 1,226

TTM EPS

₹63.9

TTM Sales

₹3,485 Cr.

Book Value per Share

₹521.7

P/E Ratio

13.18

Lower than its 5-year historical median

Industry PE

Price to Book (P/B)

1.61

Lower than its 5-year historical median

Price to Sales (P/S)

4.33

In line with its 5-year historical median

EV/EBITDA

10.57

Higher than its 5-year historical median

Dividend Yield

0.59%

Profitability Efficiency

Return on Equity (ROE)

16.30%

Outperforms industry median

Return on Capital Employed (ROCE)

17.16%

Outperforms industry median

Return on Assets (ROA)

14.13%

Operating Profit Margin

35.8%

Net Profit Margin

33.64%

Gross Profit Margin

36.1%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-12.21%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-34.52%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-27.16%

Asset Quality

Promoter Holding

49.42%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹9,308 Cr.

Equity

₹35.8 Cr.

Face Value

₹2

All Time Low / High

₹1.60 / 1638.35

Natco Pharma stock performance

Key Ratios

Check Before You Invest

Quality

Very Good

Check detailed performance

Valuation

Undervalued

Check Valuation charts

Price Trend

Semi Strong

Check Price chart

Q.1 Is Natco Pharma Ltd a good quality company?

Natco Pharma Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Natco Pharma Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Natco Pharma Ltd vs industry peers?

Natco Pharma Ltd revenue CAGR is 14.72%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Natco Pharma Ltd?

Promoters hold 49.42% of the Natco Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Natco Pharma Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 3.1% based on the current price.

DeciZen - make an informed investing decision on Natco Pharma

Consolidated basis

1. Right Stock

10 Year X-ray Pro

Long Term Prospect

2. Right Price

Price Chart

3. Right Time ⓘ

#Likely Future 5 Year CAGR.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
ROCE % ⓘ	38.7%	34.6%	23.9%	14.9%	9.5%	3.8%	16.5%	29%	33.1%	16.6%	-
Value Creation Index ⓘ	1.9	1.6	0.8	0.1	-0.3	-0.7	0.2	1.2	1.5	0.2	-
Growth Parameters ⓘ
Sales ⓘ	1,958	2,091	1,986	1,790	1,654	1,768	2,351	3,569	4,095	3,595	2,999
Sales YoY Gr.	-	6.8%	-5%	-9.9%	-7.6%	6.9%	33%	51.8%	14.7%	-12.2%	-
Adj EPS ⓘ	28.2	37.3	35	24.6	15.5	5.6	33.5	73.3	98.5	70.7	49.8
YoY Gr.	-	32.4%	-6.2%	-29.7%	-37.3%	-64.1%	503.2%	119.1%	34.3%	-28.3%	-
BVPS (₹) ⓘ	96.5	168.1	193.6	211.3	223.2	229.5	257.6	312.4	409.7	477.8	481.7
Adj Net Profit ⓘ	491	689	640	449	282	101	611	1,314	1,765	1,266	892
Cash Flow from Ops. ⓘ	330	476	699	423	184	57.7	784	1,196	1,662	1,776	-
Debt/CF from Ops. ⓘ	0.7	0.4	0.6	0.7	1.4	6.7	0.2	0.3	0.2	0.4	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	7%	16.8%	15.2%	-12.2%
Adj EPS ⓘ	10.8%	35.5%	28.3%	-28.3%
BVPSⓘ	19.5%	16.4%	22.9%	16.6%
Share Price	3.1%	-0.9%	-0.3%	-0.2%

Key Financial Parameters ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
Return on Equity % ⓘ	32.4	28.6	19.1	12.1	7.1	2.4	13.7	25.5	27.3	15.9	10.4
Op. Profit Mgn % ⓘ	35.3	44.4	41.1	32.3	25.1	12.1	34.9	46.5	52.3	37	29.1
Net Profit Mgn % ⓘ	25.1	32.9	32.2	25.1	17.1	5.7	26	36.8	43.1	35.2	29.8
Debt to Equity ⓘ	0.1	0.1	0.1	0.1	0.1	0.1	0	0.1	0	0.1	-
Working Cap Days ⓘ	169	258	328	416	458	391	308	221	228	253	272
Cash Conv. Cycle ⓘ	51	77	97	133	187	209	165	111	110	102	186

Valuation of Natco Pharma - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Sales	2,020	2,185	2,095	1,915	2,052	1,945	2,707	3,999	4,430	4,078
Operating Expenses ⓘ +	1,337	1,256	1,300	1,332	1,448	1,681	1,795	2,247	2,236	2,642
Manufacturing Costs	220	239	336	306	353	430	362	457	468	657
Material Costs	599	411	333	354	484	528	583	668	642	616
Employee Cost	243	326	356	375	415	445	487	525	595	687
Other Costs ⓘ	274	281	275	297	197	278	364	597	532	682
Operating Profit ⓘ	683	928	795	583	604	264	912	1,751	2,194	1,437
Operating Profit Margin (%)	33.8%	42.5%	37.9%	30.4%	29.4%	13.5%	33.7%	43.8%	49.5%	35.2%
Other Income ⓘ +	14	40	130	107	106	99	129	128	357	298
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	19	15	19	22	13	18	15	19	24	37
Depreciation ⓘ	54	66	81	100	117	143	164	187	235	207
Profit Before Tax ⓘ	624	887	825	569	580	202	862	1,674	2,291	1,491
Tax ⓘ	140	192	182	111	137	32	147	285	408	119
Profit After Tax	485	695	642	458	442	170	715	1,388	1,883	1,372
PAT Margin (%)	24.0%	31.8%	30.7%	23.9%	21.6%	8.7%	26.4%	34.7%	42.5%	33.6%
Adjusted EPS (₹)	27.9	37.7	35.3	25.3	24.2	9.3	39.2	77.6	105.3	79.3
Dividend Payout Ratio (%)	24.20%	21.90%	17.70%	26.70%	21.70%	48.30%	14%	12.30%	5.70%	6.30%

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Equity and Liabilities
Shareholders Fund +	1,634	3,048	3,458	3,750	4,104	4,260	4,874	5,853	7,607	9,221
Share Capital ⓘ	34.90	36.90	36.50	36.40	36.50	36.50	36.50	35.80	35.80	35.80
Reserves ⓘ	1,599	3,011	3,422	3,714	4,068	4,224	4,837	5,817	7,571	9,185
Debt +	222	173	386	314	266	404	165	363	273	406
Long Term Debt	0	0	0	0	0	0	0	0	0	100
Short Term Debt	222	173	386	314	266	404	165	363	273	306
Minority Interest	4	4	2	11	2	0	0	0	5	0
Trade Payables	263	269	217	255	146	162	264	236	275	409
Others Liabilities ⓘ	195	221	240	257	274	283	355	435	420	804
Total Liabilities ⓘ	2,318	3,715	4,303	4,588	4,792	5,109	5,657	6,887	8,581	10,841
Fixed Assets
Net Fixed Assets ⓘ +	833	1,019	1,227	1,584	2,023	2,312	2,427	2,491	2,748	2,853
Gross Block	1,159	1,408	1,695	2,149	2,702	3,127	3,375	3,603	4,015	4,256
Accumulated Depreciation	326	389	467	564	679	815	948	1,112	1,267	1,403
CWIP ⓘ	336	480	638	518	223	130	64	137	225	294
Investments ⓘ	32	77	169	112	304	308	392	539	474	3,127
Inventories	349	438	529	558	798	762	743	701	766	909
Trade Receivables	475	638	506	551	413	621	856	1,189	1,247	881
Cash Equivalents	36	184	280	66	284	206	546	953	2,176	1,551
Others Assets ⓘ	256	880	955	1,198	747	771	629	877	945	1,227
Total Assets ⓘ	2,318	3,715	4,303	4,588	4,792	5,109	5,657	6,887	8,581	10,841

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Cash Flow From Operating Activity ⓘ +	346	464	669	417	299	47	849	1,212	1,697	1,768
PBT ⓘ	624	887	825	569	580	202	862	1,674	2,291	1,491
Adjustment ⓘ	100	76	14	54	62	124	102	134	-22	30
Changes in Working Capital ⓘ	-253	-295	9	-98	-213	-231	63	-309	-200	646
Tax Paid ⓘ	-126	-205	-179	-108	-130	-48	-178	-286	-373	-398
Cash Flow From Investing Activity ⓘ +	-299	-1,116	-612	-167	-103	-5	-477	-1,033	-1,415	-2,082
Capex	-280	-407	-444	-337	-207	-179	-116	-357	-397	-390
Net Investments	-17	-569	-130	-127	36	226	-410	-736	-1,168	-1,969
Others ⓘ	-3	-140	-39	296	68	-53	49	60	150	277
Cash Flow From Financing Activity ⓘ +	-48	651	-51	-251	-186	35	-363	-247	-211	298
Net Proceeds from Shares ⓘ	0	896	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-14	0	0	0	0	0	0	0	0	400
Interest Paid ⓘ	-16	-16	-19	-22	-13	-17	-14	-18	-18	-36
Dividend Paid ⓘ	-141	-181	-92	-154	-114	-82	-100	-171	-108	-90
Others ⓘ	124	-48	60	-75	-59	134	-248	-58	-85	24
Net Cash Flow ⓘ	-1	-1	6	-1	10	76	9	-68	72	-16

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Ratios
ROE (%)	33.21	29.7	19.75	12.71	11.27	4.06	15.66	25.88	27.98	16.3
ROCE (%)	39.21	35.28	23.71	14.82	13.99	4.86	18.06	30.08	32.85	17.16
Asset Turnover Ratio	1	0.73	0.57	0.46	0.44	0.45	0.54	0.69	0.62	0.48
PAT to CFO Conversion(x)	0.71	0.67	1.04	0.91	0.68	0.28	1.19	0.87	0.9	1.29
Working Capital Days
Receivable Days	65.10	92.20	91.40	93.80	84.40	85.10	93.50	86.20	93.30	82.60
Inventory Days	62.40	65.30	77.30	96.40	118.80	128.50	95.30	60.80	56.20	65
Payable Days	164	236.10	266.70	243.30	151.50	106.40	133.20	136.40	145.20	202.80

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Natco Pharma Ltd FAQs

The current trading price of Natco Pharma on 24-Sep-2026 16:59 is ₹841.9.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Sep-2026 the market cap of Natco Pharma stood at ₹15,078.4 Cr

The latest P/E ratio of Natco Pharma as of 23-Sep-2026 is 16.90.

The latest P/B ratio of Natco Pharma as of 23-Sep-2026 is 1.75.

The 52-week high of Natco Pharma is ₹1,226.1 and the 52-week low is ₹789.3.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Natco Pharma is ₹2,999 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Natco Pharma Ltd is a good quality company.

The key valuation ratios of Natco Pharma Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Natco Pharma Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Natco Pharma Ltd

Natco Pharma is a one of the leading globally vertically integrated pharmaceutical company with decades of presence with strategic focus in research and development to manufacture niche and complex molecules. Extending its complex chemistry capabilities, it diversified into Crop Health Sciences to manufacture and supply quality crop solutions to farmers in India. The Company creates, produces and sells finished dosage formulations (FDF), active pharmaceutical ingredients (API) and agrochemicals (technical and formulation) API products are strategically used for captive consumption. In the API segment, it has capabilities to develop and manufacture products with multi step synthesis, semi synthetic fusion technologies, high- potency APIs and peptides.

Natco has two business segments, Pharmaceuticals and Agrochemicals. Pharmaceuticals constitute a major portion of the revenue, where export formulations contribute a major portion of the pharmaceutical’s revenue followed by API. Export formulations business focuses on high entry barrier and complex products and comprises of customers in US, Canada, Brazil, Asia-Pacific and other countries. API business is backward integrated making the business strategic in nature by serving its captive requirements. Capabilities in APIs include complex multi-step synthesis & scale-up, advanced synthetic/ separation technologies, containment facility for handling high potency APIs, synthesis of peptide (solid phase pharmaceuticals, oligo nucleotide pharmaceuticals etc., and a well-established process safety engineering lab.

Its R&D capabilities are demonstrated by complex and niche product filings in formulations and API segments. Agrochemicals business segment is carried under Crop Health Sciences division of the Company. It has successfully launched broadspectrum insecticide Chlorantraniliprole (CTPR) and its combination products in India across key agrarian states. It is focused on establishing a product portfolio through crop phenology analysis and also explore export opportunities.

Business area of the company

The company is engaged in the business of pharmaceuticals and agricultural chemicals which comprises research and development, manufacturing and selling of bulk drugs, finished dosage formulations. The Company has manufacturing facilities in India which caters to both domestic and international markets including regulated markets like United States of America and Europe.

Awards and accolades

2008: National Award 2008 for development of indigenous and cost-effective technologies for anti-cancer drugs by Technology Development Board, Dept. of Science & Technology, New Delhi.
2009: Gold Patents Award for the year 2008-2009.
2010: Silver Patents Award for the year 2009-2010 in recognition of commendable contribution in Bulk Drugs / API Patents Category awarded by Pharmaceuticals Export Promotion Council (PHARMEXCIL), INDIA.
2012: Best Cleaner Production Award from Andhra Pradesh Pollution Control Board (APPCB).
2013: Appreciation for Occupational Health and Safety from “NATIONAL SAFETY COUNCIL” Awards Golden Peacock Award for Corporate Social Responsibility.
2014: ‘Shreshtha Suraksha Puraskar’ National Award.
2015: Best Speciality Brand-SILVER AWARD.
2016: Golden Peacock Environment Management Award.
2017: Mr. V. C. Nannapaneni win India’s Greatest Brands and Leaders 2016-17 Awards.
2018: Mr. V. C. Nannapaneni as Best CEO among Pharmaceutical Companies.
2019: Best CEO Awards 2019 for corporate excellence.
2020: Golden Peacock Innovation Management Award.
2021: NATCO Pharma was awarded the IPA Industry Excellence Award for the year 2020.
2022: NATCO Pharma Limited receives Corporate Governance award.
2024: NATCO Pharma Awarded for Best Performance in Export Formulation.
2024: NATCO Pharma Awarded as Pioneer in Community Service.
2024: Winner of the Telangana State Awards 2023- Best CSR Practices.
2024: NATCO Pharma’s Mekaguda Unit receives GreenCo- Gold Rating.
2025: NATCO Awarded by CSR Summit.
2025: NATCO Pharma receives Best Management Award by Telangana Government.
2025: NATCO Pharma receives the Pharma Leader of the Year 2024–25 award.
2026: NATCO Pharma Receives Award from Department of Labour, Government of Telangana.

Milestone:

1981: Incorporated Natco Pharma Division at Kothur, Mahaboobnagar Dist, Telangana, India.
1984: First full year in operation- sales of Rs 0.5 million
1986: Inaugurated parental manufacturing facility at Nagarjunasagar, Telangana, India.
1993: Inaugurated Natco’s chemical division at Mekaguda in Telangana.
1995: Natco trust was founded. Natco merged three of groups companies with the parent company.
1997: Inaugurated Natco Research Center (NRC) at Sanathnagar, Hyderabad, India.
2003: Launched Oncology division with introduction of the flagship brand VEENAT (generic Imatinib Mesylate) for the treatment of chronic myelogenous leukemia.
2006: Incorporated a finished dosage facility at Dehradun, Uttrakhand.
2007: Natco launched its first ever ANDA in the US market. Natco acquired Savemart Pharmacy in USA.
2008: Natco filed its first paragraph IV filing in the US market.
2009: Inaugurated Natco Organics at Chennai, India with facilities dedicated for Cyto-toxic APIS’s Biotechnology products. Natco’s turnover reached $100 million.
2011: Incorporated Natcofarma do Brazil LTDA.
2012: Compulsory License was granted by government of India for patent protected anti-cancer drug Nexavar of Bayer.
2012: Established Natco Pharma Asia Pte Ltd for sales and distribution in Singapore and winner of Golden peacock award for CSR work.
2013: Established Natco Pharma Canada Inc for sales and distribution in Canada.
2014: Established Natco Pharma Australia Pty Ltd for sales and distribution in Australia.
2016: Sold U.S. based Save Mart pharmacy store.
2016: Winner of 'Golden Peacock Environment Management Award' for the Year 2016.
2016: Launched generic version of Oseltamivir Phosphate capsules in the United States.
2017: Started Cardiology and Diabetology divisions for domestic market with launches like Dabigatran.
2017: Launched Glatiramer Acetate injection (20 & 40 mg/ml) in the US.
2017: Launched complex drug delivery product, liposomal doxorubicin in the US.
2018: USFDA completed inspection of Natco’s Mekaguda API facility with zero observations.
2018: Natco launched its first generic version of oral tablets Teriflunomide for Multiple Sclerosis in India.
2018: Natco introduced generic Posaconazole injection, available for the first time in India.
2019: Commercial manufacturing operations begin in NATCO's Visakhapatnam Formulation Facility.
2019: Natco launches Crop Health Sciences Division.
2019: Natco Pharma invests Rs 5 crore in OMRV Hospitals.
2019: Natco Pharma has commenced commercial operations at Finished Dosage Formulations (FDF) facility in Visakhapatnam.
2020: Natco Pharma’s subsidiary -- Natco Pharma (Canada) Inc., has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide Capsules in Canada. The terms of the agreement are confidential as per the agreement.
2020: Natco Pharma has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam (Vizag) Andhra Pradesh, India.
2021: NATCO acquired Dash Pharmaceuticals LLC, now renamed as NATCO Pharma USA LLC.
2022: Crop Health Sciences division launched Chlorantraniliprole (CTPR) agro products in India.
2022: NATCO launched the first generic version of Revlimid in the USA market.
2023: NATCO set up its subsidiaries in Indonesia, United Kingdom and Colombia to boost international business.
2023: Established ‘NATCO Reach’ to expand the coverage of Cardiology and Diabetology products in India.
2024: Invested US$ 1 million in Cellogen Therapeutics Pvt Ltd. Focuses on Cell and Gene Therapy solutions.
2024: Invested US$ 8 million in eGenesis, a biotechnology company focused on xenotransplantation.
2025: Invested US$ 1 million in Stero Therapeutics, developing novel therapeutics for rare diseases with the strategic intent to further develop the therapeutics for larger, more common diseases.
2025: Further invested US$ 1 million in Cellogen Therapeutics Pvt Ltd.
2026: NATCO receives Tentative Approval for Erdafitinib Tablets (generic of Balversa) from the United States Food and Drug Administration (U.S. FDA).
2026: NATCO receives approval from Central Drug Standard Control Organisation (CDSCO) for Semaglutide in India.
2026: NATCO announces launch of Pomalidomide Capsules (generic of Pomalyst) in the U.S. market.
2026: NATCO Pharma Limited completes acquisition of additional 13.25% stake in Adcock Ingram Holdings Proprietary Limited.
2026: NATCO receives Tentative Approval for Olaparib Tablets from the United States Food and Drug Administration (U.S. FDA).

You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Natco Pharma Ltd (NATCOPHARM)

Natco Pharma Ltd (NATCOPHARM)

Natco Pharma stock performance